Taysha Gene Therapies, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company is raising money by selling new shares to investors through Jefferies and Goldman Sachs.
This legal document lets investors know details about buying 32.5 million new shares and warrants in the company.
The company is preparing to raise up to $200 million by selling shares and warrants to the public.
The company shared progress on its TSHA-102 treatment, which helps investors understand if the product is moving forward.
Shareholders voted on company matters on June 1, 2026, showing the company is following governance rules.
The quarterly report shows how much money the company made and spent in the first three months of 2026.
The company released its Q1 2026 financial performance so investors can understand how the business is doing.
Stocky reads Taysha Gene Therapies, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Taysha Gene Therapies, Inc.'s most recent tracked filing was a 8-K on 25 Jun 2026: Signs underwriting agreement for 32.5 million share offering.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.